LRRC40 Inhibitors
LRRC40 Inhibitors are a category of molecules that decrease the activity or expression of the protein encoded by the LRRC40 gene, which stands for leucine-rich repeat-containing 40. LRRC40 is a member of the leucine-rich repeat (LRR) family of proteins, a diverse group of proteins that typically engage in protein-protein interactions and are implicated in a variety of cellular processes. It is hypothesized to be involved in complex formation or signaling pathways within the cell. Inhibitors targeting LRRC40 interfere with these processes by binding directly to the protein, hence hindering its ability to interact with other proteins, or by suppressing the transcription or translation of the LRRC40 gene, thus reducing protein levels. Studies might utilize techniques like surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) to measure the affinity and thermodynamics of the interaction between LRRC40 and the inhibitors. Moreover, structural studies can map the inhibitor binding sites.
In the broader context of cellular biology, the study of LRRC40 Inhibitors would offer valuable insights into the role of LRRC proteins in the cell. By selectively modulating the function of LRRC40, researchers could explore its involvement in cellular signaling cascades or its contribution to the structural integrity of protein complexes. Such inhibitors also serve as important tools for probing the biological functions of LRRC40, potentially uncovering novel aspects of leucine-rich repeat protein biology. Furthermore, understanding the effects of LRRC40 inhibition could reveal interdependencies within cellular networks and provide a deeper understanding of the molecular underpinnings of protein-protein interactions involving LRR motifs. In essence, LRRC40 Inhibitors would not only aid in elucidating the specific functions of this particular protein but could also enhance the broader knowledge of LRR proteins as a whole within the complex milieu of the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin forms a complex with FKBP12 and inhibits mTOR (mechanistic Target Of Rapamycin), a key protein in a pathway that LRRC40 is involved in. By inhibiting mTOR, rapamycin can diminish the overall protein synthesis including that of LRRC40, leading to its reduced functional activity in the cell. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
WZB117 is a GLUT1 inhibitor that restricts glucose uptake in cells. LRRC40 is presumed to require adequate energy supply for its function; therefore, by limiting glucose entry, WZB117 indirectly diminishes the functional activity of LRRC40 through energy deprivation. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus structure, which is crucial for proper protein folding and trafficking. This disruption can lead to a decrease in the functional activity of LRRC40 by preventing its proper localization and functioning within the cell. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation in the ER. If LRRC40 undergoes glycosylation for its stability or function, this compound would lead to the production of misfolded LRRC40 proteins, thereby diminishing its functional activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Accumulation of ubiquitinated proteins can lead to ER stress and the unfolded protein response (UPR), which may include the degradation of misfolded LRRC40, indirectly diminishing its functional activity. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in protein synthesis, thus leading to decreased LRRC40 protein levels and functional activity. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
2-Deoxy-D-glucose is a glycolysis inhibitor that mimics glucose but cannot be fully metabolized, leading to energy depletion. As a result, the energy-requiring processes including those for the proper function and maintenance of LRRC40 are expected to be compromised, resulting in diminished activity of LRRC40. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin 1 is an mTOR inhibitor more potent than rapamycin. By inhibiting mTOR, it disrupts the same pathway as rapamycin, causing a decrease in LRRC40 activity due to a reduction in general protein synthesis. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin binds to Hsp90 and inhibits its chaperone function. If LRRC40 is a client protein of Hsp90, inhibition by geldanamycin would result in the destabilization and degradation of LRRC40, reducing its functional activity. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine raises the pH in endosomes/lysosomes, which can affect the trafficking of LRRC40 to the membrane, assuming LRRC40 is membrane-associated or secreted, thereby diminishing its functional activity. | ||||||